This bill amends Minnesota Statutes to introduce new provisions regarding the taxation of pharmaceutical marketing expenses. Specifically, it adds a subdivision to section 290.0131 that defines "direct-to-consumer pharmaceutical marketing" and "pharmaceutical manufacturer." It establishes that any amount deducted under section 162 of the Internal Revenue Code for direct-to-consumer pharmaceutical marketing will be treated as an addition for tax purposes. This provision is set to take effect for taxable years beginning after December 31, 2026.

Additionally, the bill amends section 290.0133 by adding a subdivision that reiterates the treatment of deductions for direct-to-consumer pharmaceutical marketing as an addition, referencing the definition provided in the new subdivision added to section 290.0131. This ensures consistency in how these marketing expenses are handled across different sections of the tax code, also effective for taxable years starting after December 31, 2026.

Statutes affected:
Introduction: 290.0131, 290.0133